Search

Your search keyword '"Qiu, Jinrong"' showing total 152 results
Start Over Author "Qiu, Jinrong"
152 results on '"Qiu, Jinrong"'

6. Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.

Author

Fan, Yun, Qiu, Jinrong, Yu, Ruoying, Cao, Ran, Chen, Xiaoxi, Ou, Qiuxiang, Wu, Xue, Shao, Yang, Nagasaka, Misako, Zhang, Jiexia, and Ou, Sai-Hong

Subjects
ERBB2, NSCLC, TMD, comprehensive genomic profiling, transmembrane domain mutation, Adenocarcinoma of Lung, Adult, Aged, Asian People, Carcinoma, Non-Small-Cell Lung, Female, Gene Amplification, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Protein Domains, Protein Multimerization, Receptor, ErbB-2, Receptor, ErbB-3, Treatment Outcome, United States
Abstract

Transmembrane domain (TMD) mutations of ERBB2 have previously been reported in lung cancer patients in addition to well-studied kinase domain (KD) mutations, which may stabilize ERBB2 heterodimerization with other EGFR family members and favor a kinase active conformation. However, the frequency and clinical significance of ERBB2 TMD mutations in Chinese population is unknown. We prospectively analyzed the next-generation sequencing data of 34 368 Chinese lung cancer patients with different sample types, including tumor tissue, plasma, cerebrospinal fluid, and pleural effusion. Patients clinical characteristics and treatment history were retrieved from the database for further evaluation. Our findings show that ERBB2 V659/G660 mutations were detected at a frequency of 0.13% (45/34 368), of which the most frequent was V659D/E (88.9%), with a trend in nonsmokers and male. Moreover, 18% of patients (8/45) showed EGFR and/or ERBB2 amplification, whereas nine patients presented EGFR L858R or exon19 deletion. Interestingly, novel ERBB3 TMD mutation I646R was found coexisting in three patients with ERBB2 V659D and one patient with ERBB2 G660D, which might influence its heterodimerization with ERBB2 and further activate ERBB2. Four ERBB2 TMD mutation-positive patients received afatinib monotherapy or combination therapy, but showed variable responses. One patient with V659E responded well to ERBB2 inhibitor lapatinib plus capecitabine as well as subsequent afatinib treatment upon progression. Our study provides valuable insights into the distribution of ERBB2 TMD mutations by employing the largest Asian lung cancer cohort thus far. Patients with ERBB2 TMD mutations who received afatinib, a pan-ERBB inhibitor, demonstrated mixed responses, posing the urgent need to develop more effective therapeutic strategy for patients who carry ERBB2 TMD mutations.

Published
2020

8. Development of a Specific Aptamer‐Modified Nano‐System to Treat Esophageal Squamous Cell Carcinoma.

Author

Xie, Fei, Qiu, Jinrong, Sun, Congyong, Feng, Lulu, Jun, Yali, Luo, Chao, Guo, Xiamei, Zhang, Bowei, Zhou, Yu, Wang, Yuting, Zhang, Li, and Wang, Qilong

Subjects
*APTAMERS, *SQUAMOUS cell carcinoma, *SMALL interfering RNA, *GASTROINTESTINAL cancer, *EGG yolk, *LUNG tumors, *SURVIVAL rate
Abstract

Esophageal squamous cell carcinoma (ESCC) is a prevalent gastrointestinal cancer characterized by high mortality and an unfavorable prognosis. While combination therapies involving surgery, chemotherapy, and radiation therapy are advancing, targeted therapy for ESCC remains underdeveloped. As a result, the overall five‐year survival rate for ESCC is still below 20%. Herein, ESCC‐specific DNA aptamers and an innovative aptamer‐modified nano‐system is introduced for targeted drug and gene delivery to effectively inhibit ESCC. The EA1 ssDNA aptamer, which binds robustly to ESCC cells with high specificity and affinity, is identified using cell‐based systematic evolution of ligands by exponential enrichment (cell‐SELEX). An EA1‐modified nano‐system is developed using a natural egg yolk lipid nanovector (EA1‐EYLNs‐PTX/siEFNA1) that concurrently loads paclitaxel (PTX) and a small interfering RNA of Ephrin A1 (EFNA1). This combination counters ESCC's proliferation, migration, invasion, and lung metastasis. Notably, EFNA1 is overexpressed in ESCC tumors with lung metastasis and has an inverse correlation with ESCC patient prognosis. The EA1‐EYLNs‐PTX/siEFNA1 nano‐system offers effective drug delivery and tumor targeting, resulting in significantly improved therapeutic efficacy against ESCC tumors. These insights suggest that aptamer‐modified nano‐systems can deliver drugs and genes with superior tumor‐targeting, potentially revolutionizing targeted therapy in ESCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. High-throughput sequencing approach for the identification of lncRNA biomarkers in hepatocellular carcinoma and revealing the effect of ZFAS1/miR-150-5p on hepatocellular carcinoma progression

Author

Zhu, Peng, primary, Pei, Yongyan, additional, Yu, Jian, additional, Ding, Wenbin, additional, Yang, Yun, additional, Liu, Fuchen, additional, Liu, Lei, additional, Huang, Jian, additional, Yuan, Shengxian, additional, Wang, Zongyan, additional, Gu, Fangming, additional, Pan, Zeya, additional, Chen, Jinzhong, additional, Qiu, Jinrong, additional, and Liu, Huiying, additional

Published
2023
Full Text
View/download PDF

17. A single-arm, open-label, phase II study investigating anti-HER2 ADC plus anti-PD-1 antibody in patients with unresectable locally advanced or metastatic BTC with HER2 overexpression.

Author

Chen, Xiaofeng, primary, Guo, Fen, additional, Zhang, Xinyi, additional, Qiu, Jinrong, additional, Zheng, Tongsen, additional, Qiu, Hong, additional, Tian, Yitong, additional, Pan, Lanlan, additional, Zhang, Jiaguang, additional, Chen, Yizhang, additional, Shen, Haoyang, additional, and Wang, Chao, additional

Published
2023
Full Text
View/download PDF

41. Changes and Clinical Significance of Detailed Peripheral Lymphocyte Subsets in Evaluating the Immunity for Cancer Patients

Author

Qiu,Jinrong, Zhou,Fuping, Li,Xinchun, Zhang,Sufang, Chen,Zhuo, Xu,Zenghui, Lu,Gaoxiong, Zhu,Zhi, Ding,Na, Lou,Jinxing, Ye,Zhenlong, and Qian,Qijun

Subjects
Cancer Management and Research
Abstract

Jinrong Qiu, 1,* Fuping Zhou, 1,* Xinchun Li, 2,* Sufang Zhang, 2 Zhuo Chen, 2 Zenghui Xu, 2 Gaoxiong Lu, 2 Zhi Zhu, 3 Na Ding, 2 Jinxing Lou, 4 Zhenlong Ye, 2 Qijun Qian 1, 2, 4 1Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University of Chinese PLA, Shanghai, People’s Republic of China; 2Shanghai Baize Medical Laboratory, Shanghai, People’s Republic of China; 3Department of Pathology, Changhai Hospital, The Second Military Medical University of Chinese PLA, Shanghai, People’s Republic of China; 4Shanghai Mengchao Cancer Hospital, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Qijun Qian; Zhenlong YeShanghai Baize Medical Laboratory, Yuanguo Road, Shanghai 201805, People’s Republic of ChinaEmail qian@shcell.org; yezl@shcell.orgObjective: The evaluation of lymphocyte subsets is widely regarded as an important factor for monitoring tumor progression and response to therapy. This study was designed to establish a comprehensive and detailed assessment of peripheral lymphocyte subsets with a multi-parametric flow cytometry assay for response prediction and prognosis evaluation of cancer patients.Methods: Peripheral blood samples collected from 40 cancer patients and 23 age- and sex-matched healthy volunteers were tested for 29 lymphocyte subsets by flow cytometry. The univariate analysis was applied to establish the reference interval of healthy samples, and the ratio and proportion of 29 lymphocyte subsets between patient samples and healthy controls were compared to evaluate their clinical significance by Mann–Whitney U-test model.Results: The reference ranges of 29 lymphocyte subsets were established with a normal distribution and no significant differences were observed between genders. Compared with healthy control group, lower proportion and ratio of specific parameters, such as Naïve Th cells (p< 0.01), Naïve Tc cells (p< 0.01), CM (central memory) Tc cells (p< 0.01), Naïve T cells/Memory T cells (p< 0.001), Naïve T cells/EM (effector memory) T cells (p< 0.001) and Naive Th cells/Memory Th cells (p< 0.001), and higher proportion and ratio of EM Th cells (p< 0.001), EM Tc cells (p< 0.01), effector Tc cells (p< 0.05), EM Th cells/CM Th cells (p< 0.01) and EM Tc cells/CM Tc cells (p< 0.01), as well as Breg (p< 0.001), B cells (p< 0.05) and CD16-NK cells (p< 0.001) were found in cancer cohorts.Conclusion: This study suggests that the changes in certain lymphocyte subsets might be helpful to evaluate the immunity of cancer patients, and holds great potential for clinical application.Keywords: solid tumor, lymphocyte subsets, clinic significance, reference intervals, flow cytometry &nbsp

Published
2020

50. Transient Simulation Modeling of Condenser Based on Thermal System Dynamics

Author

Qiu Jinrong and Lin Yuansheng

Subjects
Materials science, Differential equation, Mass transfer, Simulation modeling, Thermal, Mechanics, Transient (oscillation), Condenser (heat transfer), System dynamics
Abstract

Complex process such as heat transfer, mass transfer and flow is occurring in the condenser, simulation analysis is an effective method of studying its dynamical character. Conventionally, simulation of condenser is modeled basing on thermal system static, the content and depth of research is not enough. Aiming at understanding its transient character deeply, condenser modeling is carried out basing on the view and method of thermal system dynamics, the parameter of the object is treated as coupling parameter. Adapting a set of ordinary differential equations, the model can reflect the transient character of condenser effectively. The model can reflect the coupling relationship between the parameters which can’t be obtained through the previous simulation model. The model has simple form and can be computed conveniently.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results